Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights
Rhea-AI Summary
Arcadia Biosciences (Nasdaq: RKDA) reported Q4 and full-year 2025 results and business updates on March 26, 2026. The company said it received a termination notice for the proposed Roosevelt Resources business combination and raised approximately $2.1 million from exercise of preferred investment options.
Zola coconut water revenues rose 17% YoY. SG&A expense declined ~27%, net cash used in operating activities fell 49%, Q4 revenue was $0.9M vs $1.2M prior year, and full-year revenue was $4.858M vs $5.045M in 2024. Q4 net loss attributable to common stockholders was $1.336M (Q4 2024: $4.064M).
Positive
- Zola revenue growth of 17% YoY
- SG&A expense reduction of ~27%
- Net cash used in operations declined by 49%
- Raised approximately $2.1 million from preferred option exercises
- Q4 net loss improved from $4.064M to $1.336M (67% improvement)
Negative
- Total revenues declined 26% in Q4 (Q4 2025: $0.901M vs Q4 2024: $1.216M)
- Full-year revenue declined 4% (2025: $4.858M vs 2024: $5.045M)
- Termination of proposed Roosevelt Resources business combination introduces strategic uncertainty
News Market Reaction – RKDA
In the Mar 27 session, RKDA declined 3.29%, reflecting a moderate negative market reaction. Argus tracked a peak move of +11.7% during that session. Argus tracked a trough of -12.0% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 07 | Q3 2025 earnings | Neutral | -2.2% | Mixed Q3 2025 performance with Zola growth and balance sheet actions. |
| Aug 14 | Q2 2025 earnings | Neutral | +5.6% | Q2 2025 revenue growth, Above Food shares, and large credit loss. |
| May 08 | Q1 2025 earnings | Positive | -0.2% | Strong Q1 revenue, 90% Zola growth, shift from loss to net income. |
| Mar 20 | FY/Q4 2024 earnings | Neutral | -4.5% | Robust 2024 Zola growth and asset sales with continued net losses. |
| Nov 12 | Q3 2024 earnings | Positive | -1.2% | Q3 2024 revenue growth, expanding Zola distribution, narrower net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings headlines have often been met with modestly negative or muted price reactions, even when operational trends for Zola and expenses improved.
Over the past five earnings cycles (Nov 2024–Nov 2025), Arcadia emphasized growth in its Zola coconut water brand, consistent gross margins above 30%, and operating expense reductions. Results have alternated between strong revenue growth periods and mixed quarters with credit losses and business-combination updates. Price reactions to these earnings events have generally been small, with an average move of about -0.51%, suggesting limited historical re-rating on financial updates alone.
Key Terms
preferred investment options financial
Securities Exchange Agreement regulatory
SG&A financial
contingent liability financial
Form 8-K regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
-- Zola® revenues increase
-- Arcadia and Roosevelt Resources terminate proposed business combination --
-- Exercise of preferred investment options yields
DALLAS, March 26, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the fourth quarter and full year of 2025.
“At the end of 2025, we received a termination notice from Roosevelt Resources related to the Securities Exchange Agreement concerning a proposed business combination, signed in December 2024.” said T.J. Schaefer, CEO of Arcadia.
Schaefer continued, “After receiving this news, we took steps to improve our balance sheet by entering into definitive agreements for the immediate exercise of certain outstanding preferred investment options, resulting in gross proceeds of approximately
“In 2025, Zola sales growth continued to outpace the coconut water category. At the same time, we reduced our SG&A expenses by approximately
| Arcadia Biosciences, Inc. | ||||||||||||||||||
| Financial Snapshot | ||||||||||||||||||
| (Unaudited) | ||||||||||||||||||
| ($ in thousands) | ||||||||||||||||||
| Three months ended Dec 31 | Twelve months ended Dec 31 | |||||||||||||||||
| 2025 | 2024 | Favorable/ (Unfavorable) | 2025 | 2024 | Favorable/ (Unfavorable) | |||||||||||||
| $ | % | $ | % | |||||||||||||||
| Total Revenues | 901 | 1,216 | (315 | ) | (26 | %) | 4,858 | 5,045 | (187 | ) | (4 | %) | ||||||
| Total Operating Expenses | 2,276 | 3,495 | 1,219 | 35 | % | 7,358 | 8,693 | 1,335 | 15 | % | ||||||||
| Loss From Continuing Operations | (1,375 | ) | (2,279 | ) | 904 | 40 | % | (2,500 | ) | (3,648 | ) | 1,148 | 31 | % | ||||
| Net Loss Attributable to Common Stockholders | (1,336 | ) | (4,064 | ) | 2,728 | 67 | % | (2,339 | ) | (7,038 | ) | 4,699 | 67 | % | ||||
Certain previously reported financial information has been reclassified to conform to the current year presentation. Reclassifications are related to the presentation of the financial results of our former GoodWheat™ brand as discontinued operations. The financial information above and narrative that follows relate to continuing operations unless stated otherwise.
More detailed financial statements are included in the Form 8-K filed today, available in the Investors section of the company’s website under SEC Filings.
Revenues
Revenues decreased by
Revenues for the full year of 2025 decreased
Operating Expenses
Cost of revenues decreased by
Selling, general, and administrative (SG&A) expenses decreased by
Other operating expenses increased by
Net Loss Attributable to Common Stockholders
Net loss attributable to common stockholders for the fourth quarter of 2025 was
Net loss attributable to common stockholders for 2025 was
About Arcadia Biosciences, Inc.
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products. For more information, visit www.arcadiabio.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future results of operations concerning the company and its products, including, but not limited to, statements relating to the company’s growth, cash position, operating costs, financial performance, and the impact on shareholder value. Undue reliance should not be placed on any forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from the results anticipated by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks set forth in filings that the company makes with the Securities and Exchange Commission from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2025 (the 2025 Form 10-K), and other filings that the company makes with the SEC. Forward-looking statements concerning anticipated future activities also assume that the company has sufficient funding to continue its operations and planned activities, which may not be the case. As described in greater detail in the 2025 Form 10-K, the company will require additional funding in the near future to continue its operations and planned activities. There are no assurances that required funding will be available at all or will be available in sufficient amounts or on reasonable terms. The company may seek to raise additional funds through equity or debt financings, through transactions involving its other assets, or through other transactions. Any sale of additional equity securities could result in dilution to company stockholders. Reported results should not be considered as an indication of future performance. Forward-looking statements made in this press release speak only as of the date hereof, and except as required by law, Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements or to reflect events or circumstances arising after the date of this press release.
Arcadia Biosciences Contact:
T.J. Schaefer
ir@arcadiabio.com
